Tirzepatide
Also known as: Mounjaro, Zepbound
Dual GIP/GLP-1 Receptor Agonist | Weight Loss & Diabetes
Overview
Revolutionary dual receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Demonstrates efficacy superior to single-mechanism alternatives with 15-22% body weight reduction in clinical trials. The first-in-class dual GIP/GLP-1 agonist provides enhanced metabolic benefits compared to GLP-1-only medications.
Key benefits
- Dramatic weight loss (15-22% body weight)
- Superior diabetes control
- Reduced cardiovascular risk (26% reduction in MACE)
- Improved insulin sensitivity
- Appetite suppression
- Preserved muscle mass with exercise
Mechanism of action
Dual agonist targeting both GIP and GLP-1 receptors, producing glucose-dependent insulin stimulation, delayed gastric emptying, glucagon suppression, and central satiety signaling via hypothalamic pathways.
Molecular data
- Type
- Dual GLP-1/GIP agonist
- Half-life
- ~5 days (120 hours)
Sequence
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-Gly-Gly-Gly-Gly-Pro-Ser-Lys-Lys-Lys-Lys-Lys-Lys
Indications
What the research community uses this compound for, with self-reported effectiveness.
Weight Loss
Severe Obesity Management
Most effectiveClinical trials demonstrate 15-22% body weight reduction in non-diabetic obese individuals, superior to existing weight loss medications.
Metabolic Syndrome Reversal
Most effectiveImprovements in waist circumference, blood pressure, triglycerides, HDL cholesterol, and insulin resistance markers.
Body Composition Optimization
EffectivePreferentially reduces visceral adipose tissue while preserving lean muscle mass with resistance training.
Diabetes
Type 2 Diabetes Management
Most effectiveSuperior HbA1c reduction of 1.5-2.4% in clinical trials.
Insulin Resistance Improvement
EffectiveImproves insulin sensitivity across diverse populations.
Beta Cell Preservation
EffectiveMay help preserve and restore pancreatic beta cell function.
Cardiovascular
MACE Reduction
Effective26% reduction in major adverse cardiovascular events demonstrated in SURPASS-CVOT trial.
Blood Pressure Reduction
EffectiveSystolic and diastolic blood pressure reductions of 8-12 mmHg.
Lipid Profile Improvement
ModerateTriglyceride improvements of 20-30%, HDL enhancement, and apolipoprotein B reduction.
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Injectable
Once-weekly subcutaneous injection. Can be taken any time of day, with or without food. Injection sites include thigh, abdomen (2+ inches from navel), or upper arm.
| Protocol | Dose | Frequency | Route / duration |
|---|---|---|---|
| Weight loss initiation | 2.5mg | Once weekly x 4 weeks | SubQ injection |
| Weight loss progression | 5mg | Once weekly | SubQ injection |
| Weight loss optimization | 7.5-10mg | Once weekly | SubQ injection |
| Maximum weight loss | 12.5-15mg | Once weekly | SubQ injection |
| Diabetes management (mild) | 5-7.5mg | Once weekly | SubQ injection |
| Diabetes management (severe) | 10-15mg | Once weekly | SubQ injection |
Preparation
You will need
- Tirzepatide lyophilized powder vial (or pre-filled pen)
- Bacteriostatic water for injection
- Insulin syringes (0.5ml or 1ml with fine needle)
- Alcohol prep pads
- Sterile work surface
Steps
- Allow vial to reach room temperature (15-20 minutes)
- Clean vial tops with alcohol wipes, allow air drying
- Calculate reconstitution volume
- Draw bacteriostatic water carefully into syringe
- Insert needle at 45-degree angle against glass wall
- Inject water slowly down vial side to prevent foaming
- Gently swirl—never shake vigorously
- Allow 2-3 minutes for clearing if cloudiness appears
- Final solution must be completely clear and colorless
- Label with date and concentration
- Store at 2-8°C, use within 28 days
Work out the water volume and syringe units in the reconstitution calculator →
Interactions
Pairwise interactions with other compounds you might be cycling — the same data behind the cycle builder's safety check.
Semaglutide
AvoidBoth are GLP-1 agonists—combining increases hypoglycemia and severe GI side effect risk.
Liraglutide
AvoidAnother GLP-1 agonist—dual therapy contraindicated due to additive effects.
Insulin
MonitorMay require significant insulin dose reduction due to improved sensitivity.
Metformin
SynergisticComplementary mechanisms for diabetes management and weight loss.
CJC-1295
CompatibleGrowth hormone support may help preserve muscle mass during weight loss.
Ipamorelin
CompatibleMay help maintain metabolic rate and muscle preservation.
BPC-157
CompatibleNo known interactions, may support gut health and reduce GI effects.
5-Amino-1MQ
CompatibleNNMT inhibition may complement GLP-1 effects for metabolic optimization.
Timeline
Typical week-by-week effects reported in clinical and observational data.
- Day 1-3
Appetite reduction begins
- Week 1-2
Improved blood sugar control (diabetics), mild nausea common
- Week 2-4
Initial weight loss begins; GI side effects typically improve
- Ongoing
1-3 lbs weight loss per week during active phase
- Week 16-24
Peak weight loss effects observed
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Nausea (mild to moderate, first 2-4 weeks)
- Appetite reduction
- Possible fatigue during adaptation
- Diarrhea or constipation
- Reduced food cravings
Stop signs — stop and seek advice
- Severe/persistent abdominal pain (pancreatitis risk)
- Neck lumps, hoarseness, difficulty swallowing (thyroid concerns)
- Severe nausea/vomiting preventing adequate nutrition
- Severe hypoglycemic signs (confusion, sweating, rapid heartbeat)
- Kidney problems (decreased urination, swelling)
- Severe allergic reactions (rash, breathing difficulty)
- Suicidal thoughts or severe depression
- Gallbladder problems (severe upper right pain)
- Dehydration from persistent vomiting
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Pregnancy or breastfeeding
- History of pancreatitis
Monitoring
- Start with lowest dose (2.5mg) and escalate every 4 weeks
- May require diabetes medication adjustment to prevent hypoglycemia
- Monitor for pancreatitis symptoms
Quality checks
What a legitimate product looks like, what should give pause, and what should make you stop.
Good signs
- White to off-white lyophilized powder without clumping
- Clear, colorless reconstituted solution
- Intact vial seal with visible mg dosage labeling and batch numbers
- Proper storage maintenance at 2-8°C, protected from light
Warning signs
- Compounded versions without proper quality control
Stop signs — don't use
- Powder clumping, discoloration, or yellow/brown appearance
- Persistent cloudiness after reconstitution
- Unusual crystallization patterns
Recent research
Newer papers and trial readouts on file for this compound, with source and date.
2025-12
SURPASS-CVOT Results Published
Landmark cardiovascular outcomes trial published in NEJM showing tirzepatide noninferior to dulaglutide for MACE in 13,299 patients with T2DM and atherosclerotic CVD, with favorable trends in secondary endpoints including all-cause mortality.
2025-05
SURMOUNT-5 Head-to-Head vs Semaglutide
First direct comparison published in NEJM demonstrating tirzepatide superior to semaglutide for weight loss (20.2% vs 13.7%) and waist circumference reduction at 72 weeks in adults with obesity.
2025-03
3-Year SURMOUNT-1 Extension for Diabetes Prevention
Three-year data showing sustained weight loss up to 19.7% and 93% reduction in progression to type 2 diabetes in persons with obesity and prediabetes treated with tirzepatide.
2024-11
SUMMIT Trial: Heart Failure Benefits
Phase 3 SUMMIT trial showed tirzepatide reduced composite of CV death or worsening heart failure by 38% in patients with HFpEF and obesity, establishing cardiovascular benefits beyond weight loss.
References
Primary literature and clinical-trial data informing this entry.
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff, A.M., et al. · New England Journal of Medicine · 2022
Participants: 2,539 adults with obesity
Landmark phase 3 trial: 15mg weekly achieved 22.5% weight loss vs 2.4% placebo over 72 weeks. Weight reduction of ≥20% achieved in 57% of 15mg recipients.
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
Frías, J.P., et al. · New England Journal of Medicine · 2021
Participants: 1,879 patients with type 2 diabetes
Tirzepatide was noninferior and superior to semaglutide 1mg for HbA1c reduction and weight loss in type 2 diabetes. The 15mg dose achieved nearly twice the weight loss of semaglutide.
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)
Garvey, W.T., et al. · The Lancet · 2023
Participants: 938 adults with T2DM and obesity
15mg dose achieved 15.7% weight loss over 72 weeks with significant cardiometabolic improvements. 79-83% of tirzepatide recipients achieved ≥5% weight loss vs 32% placebo.
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT)
Nicholls, S.J., et al. · New England Journal of Medicine · 2025
Participants: 13,299 patients with T2DM and atherosclerotic CVD
Tirzepatide was noninferior to dulaglutide for MACE (composite of CV death, MI, or stroke). Several secondary endpoints favored tirzepatide, including reduced all-cause mortality after 4-year median follow-up.
Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 3-Year Extension)
Jastreboff, A.M., et al. · New England Journal of Medicine · 2025
Participants: 1,032 participants with obesity and prediabetes
Three years of tirzepatide resulted in sustained weight reduction of up to 19.7% (15mg) and 93% lower risk of progression to type 2 diabetes vs placebo (HR 0.07).
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT)
Packer, M., et al. · New England Journal of Medicine · 2024
Participants: 731 patients with HFpEF and obesity
Tirzepatide reduced the composite of CV death or worsening heart failure by 38% (HR 0.62) vs placebo over median 104 weeks. Improved health status scores and 6-minute walk distance.
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)
Aronne, L.J., et al. · New England Journal of Medicine · 2025
Participants: Adults with obesity without type 2 diabetes
Head-to-head comparison: tirzepatide achieved 20.2% weight loss vs 13.7% with semaglutide at 72 weeks. Tirzepatide was superior for body weight and waist circumference reduction.
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA)
Malhotra, A., et al. · New England Journal of Medicine · 2024
Participants: Adults with moderate-to-severe OSA and obesity
Tirzepatide significantly reduced AHI with resolution of OSA in approximately 50% of participants. Also reduced body weight, hypoxic burden, hsCRP, and systolic blood pressure.
Last updated . How this page was sourced is described in the methodology.
Featured in these stacks
- Dual-Incretin + AmylinAn advanced fat-loss stack pairing tirzepatide with the amylin analogue cagrilintide — different mechanisms, additive appetite control.2 compounds
- GLP-1 Fat-Loss StarterA single-agent, titrate-slowly approach to appetite-led fat loss built around one GLP-1 — the lowest-complexity place to start.2 compounds